@HebrewUniv Tag

23 Sep

Posted at 18:50h in Accidents & Violence, Cocaine

MedicalResearch.com Interview with:

[caption id="attachment_76205" align="alignleft" width="125"]Dr. Ben Jerry Gonzales Dr. Ben Jerry Gonzales[/caption]

Dr. Ben Jerry Gonzales PhD

[caption id="attachment_76206" align="alignleft" width="125"]Mr. Itay Shalom Mr. Itay Shalom[/caption] [caption id="attachment_76207" align="alignleft" width="113"]Prof. Ami Citri.jpg Prof. Ami Citri.jpg[/caption]

Mr. Itay Shalom

Prof. Ami Citri PhD

Citri Laboratory, Hebrew University of Jerusalem

When mice were repeatedly exposed to high doses of cocaine in a new study from the Hebrew University of Jerusalem, their diverse behavioral repertoire progressively narrowed until a single action dominated: licking the floor and walls of the arena. By the fifth day of exposure, the animals spent approximately 62% of their time performing this one repetitive behavior. The research, published in Current Biology, identifies the striatal circuit mechanism driving this behavioral capture and demonstrates that manipulating the circuit can interrupt cocaine-induced rigidity within a second. According to the NIDA (National Institute on Drug Abuse), cocaine exerts its behavioral effects primarily through dopaminergic circuits in the basal ganglia, and understanding how those circuits translate drug exposure into compulsive, repetitive behavior is a central question in addiction neuroscience.

09 Sep

Posted at 17:01h in Author Interviews, Genetic Research
[caption id="attachment_75927" align="alignleft" width="200"]Aerial view of the Rothberg amphitheater Hebrew University photo by Maxime Dinshtein[/caption]

MedicalResearch.com Interview with:

Wisam Zaatra, PhD Student, and Prof. Batsheva Kerem Hebrew University of Jerusalem

George Philippos, PhD Student, and Prof. Aurélie Ernst German Cancer Research Center (DKFZ) and Heidelberg University

View the video presentation of this interview

06 Mar

Posted at 20:47h in Author Interviews, Cannabis, Hepatitis - Liver Disease
Editor’ note:  Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider.  Dosing of Cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles, drinks and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. MedicalResearch.com Interview with: Prof. Joseph (Yossi) Tam, DMD, PhD School of Pharmacy, Institute for Drug Research The Hebrew University of Jerusalem The Harvey M. Krueger Family Center for Nanoscience and Nanotechnology Jerusalem, IsraelProf. Joseph (Yossi) Tam, DMD, PhDSchool of Pharmacy, Institute for Drug Research The Hebrew University of Jerusalem The Harvey M. Krueger Family Center for Nanoscience and Nanotechnology Jerusalem, Israel With colleagues Dr. Liad Hinden, the PhD student Radka Kočvarová, and the Tam’s team at the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem.   MedicalResearch.com: What is the background for this study? Would you describe the condition of Metabolic dysfunction-associated steatotic liver disease (MASLD)? What causes it? Whom does it affect? Response: MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disorder worldwide. It develops when fat accumulates excessively in liver cells, commonly in people with obesity, insulin resistance, high cholesterol, or diabetes. Over time, this condition can progress to inflammation, fibrosis, or cirrhosis. Despite its growing prevalence, effective pharmacological therapies remain limited, leaving a substantial unmet clinical need.

18 Feb

Posted at 18:24h in Author Interviews, Infections, Obstructive Sleep Apnea, Pediatrics
MedicalResearch.com Interview with: [caption id="attachment_72499" align="alignleft" width="174"]Dr. Alex Gileles-Hillel MDFounder and director of Gileles Lab Hadassah Medical Center Dr. Gileles-Hillel[/caption] Dr. Alex Gileles-Hillel MD Founder and director of Gileles Lab Hadassah Medical Center Along with Dr. Joel Reiter MD from the Faculty of Medicine Hebrew University and Senior Pediatric Pulmonologists at the Hadassah Medical Center with Dr. David Gozal MD, MBA, PhD from Marshall University MedicalResearch.com: What is the background for this study? Response: Children with Obstructive Sleep Apnea (OSA) experience increased morbidity, including cognitive difficulties, daytime dysfunction, and poorer academic performance, as well as a higher risk of future cardiometabolic disease such as hypertension and obesity. In addition, pediatric OSA has been shown to impair immune responses and alter immunologic function, although the clinical consequences of these changes remain incompletely understood.